Business Wire
-
Drug Discovery Research Turns To Biomarkers
9/25/2008
The total drug discovery market in Western Europe was worth $17.40 billion in 2007, and Frost & Sullivan expects this to grow at a compound annual growth rate of 13.5% to reach $42.08 billion by 2014
-
Curis Announces Dosing Of First Patient In Phase I Clinical Trial Of CUDC-101
8/26/2008
Curis, Inc.a drug development company focused on developing next generation proprietary targeted medicines for cancer treatment today announced that the first patient has been treated in a Phase I clinical trial of CUDC-101, a first-in-class small molecule drug candidate that has been designed as an inhibitor of epidermal growth factor receptor
-
Cellumen And Mitsubishi Tanabe Pharma Corporation Collaborate In Discovery Toxicology
8/19/2008
Cellumen, Inc., a discovery toxicology company,announced an agreement with Mitsubishi Tanabe Pharma Corporation, one of the leading pharmaceutical companies in Japan, to develop panels of biomarkers that identify toxicity early in the drug development process
-
Mallinckrodt Baker And Rubicon Research Sign Agreement For Performance Excipient Development
8/18/2008
Covidien, a leading global provider of healthcare products, today announced that its Mallinckrodt Baker business has entered into a licensing and commercialization agreement with drug development research specialist Rubicon Research
This website uses cookies to ensure you get the best experience on our website. Learn more